Cabozantinib: a new perspective for advanced bone sarcoma.,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cabozantinib: a new perspective for advanced bone sarcoma.
The Lancet Oncology ( IF 41.6 ) Pub Date : 2020-02-17 , DOI: 10.1016/s1470-2045(20)30004-8
Franca Fagioli ₁ , Elisa Tirtei ₁

Affiliation

Current multimodal therapeutic approaches have improved the prognosis of patients with Ewing sarcoma and osteosarcoma, with a 5-year overall survival rate of around 60–70%. ^, ^, Nevertheless, patients with recurrent or refractory disease have a poor prognosis, with a 5-year overall survival rate of less than 30%. ^, A consensus regarding the standard management of patients with recurrent or refractory disease has yet to be obtained and new drugs are needed.

中文翻译：